Biomarin Pharmaceutical Inc (NASDAQ: BMRN)’s stock price has soared by 0.09 in relation to previous closing price of 70.54. Nevertheless, the company has seen a loss of -0.86% in its stock price over the last five trading days. zacks.com reported 2025-03-12 that Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
Is It Worth Investing in Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Right Now?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has a higher price-to-earnings ratio of 32.10x compared to its average ratio, The 36-month beta value for BMRN is at 0.30. Analysts have varying views on the stock, with 16 analysts rating it as a “buy,” 7 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for BMRN is 188.34M, and currently, shorts hold a 2.25% of that float. The average trading volume for BMRN on March 14, 2025 was 1.53M shares.
BMRN’s Market Performance
BMRN stock saw an increase of -0.86% in the past week, with a monthly gain of 11.09% and a quarterly increase of 5.67%. The volatility ratio for the week is 2.54%, and the volatility levels for the last 30 days are 2.89% for Biomarin Pharmaceutical Inc (BMRN). The simple moving average for the last 20 days is 1.89% for BMRN’s stock, with a simple moving average of -4.37% for the last 200 days.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Oppenheimer repeating the rating for BMRN by listing it as a “Outperform.” The predicted price for BMRN in the upcoming period, according to Oppenheimer is $98 based on the research report published on February 24, 2025 of the current year 2025.
Wolfe Research, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $95. The rating they have provided for BMRN stocks is “Outperform” according to the report published on November 15th, 2024.
BMRN Trading at 6.61% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.57% of loss for the given period.
Volatility was left at 2.89%, however, over the last 30 days, the volatility rate increased by 2.54%, as shares surge +7.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.55% upper at present.
During the last 5 trading sessions, BMRN fell by -0.86%, which changed the moving average for the period of 200-days by -6.98% in comparison to the 20-day moving average, which settled at $69.29. In addition, Biomarin Pharmaceutical Inc saw 7.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Guyer Charles Greg, who sale 7,034 shares at the price of $71.28 back on Mar 06 ’25. After this action, Guyer Charles Greg now owns 87,655 shares of Biomarin Pharmaceutical Inc, valued at $501,355 using the latest closing price.
Guyer Charles Greg, the Officer of Biomarin Pharmaceutical Inc, proposed sale 7,034 shares at $71.28 during a trade that took place back on Mar 06 ’25, which means that Guyer Charles Greg is holding shares at $501,359 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.79 for the gross margin
The net margin for Biomarin Pharmaceutical Inc stands at 0.15. The total capital return value is set at 0.07. Equity return is now at value 8.05, with 6.17 for asset returns.
Based on Biomarin Pharmaceutical Inc (BMRN), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.95. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is 37.33.
Currently, EBITDA for the company is 650.53 million with net debt to EBITDA at -0.52. When we switch over and look at the enterprise to sales, we see a ratio of 4.61. The receivables turnover for the company is 4.32for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.33.
Conclusion
In conclusion, Biomarin Pharmaceutical Inc (BMRN) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
